Business
Interim Results
Venture Life Group PLC reported unaudited interim results for the period ended 30 June 2025, showing a 43.1% increase in Group revenue to £15.4 million. Gross profit rose by 49.9% to £6.6 million, with a gross margin improvement to 43.1%. Adjusted EBITDA increased by 32.6% to £1.8 million. The company reported an operating loss of £1.4 million, but adjusted profit before tax increased to £0.8 million. Adjusted EPS increased to 0.83p, while basic EPS decreased to a loss of (1.53)p. Free cash flow decreased to £1.5 million. Group net debt increased to £19.9 million, but post-period end, the Group reports a net cash position of £34.1 million following the sale of its CDMO to BioDue S.p.A for €62 million in cash. The company intends to launch a share buyback programme. Disclaimer*
About this update from Venture Life Group Plc
[{"type":"text","content":"\n\n30 September 2025\n \nTHIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. WITH THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n\n \nVENTURE LIFE GROUP PLC\n \n(\"Venture Life\", \"VLG\" or the \"Group\")\n \n Unaudited Interim Results for period ended 30 June 2025\n \nIntention to launch share buyback programme\n \nVenture Life (AIM: VLG), a recognised leader in proactive healthy longevity, product innovation, development, and commercialisation within the global consumer healthcare sector, announces its unaudited results for the period ended 30 June 2025 (the \"Period\"). The Group delivered robust revenue growth from continuing operations, driven by strategic marketing investments.\n \nIn July 2025, the Company sold its contract development and manufacturing operations (\"CDMO\") and certain non-core products (the \"Non-Core Products\") to BioDue S.p.A for €62 million in cash. The Group is also seeking to sell its oral care brands, which, along with the CDMO and non-core products, form the discontinued operations (the \"Discontinued Operations\"). These are reported separately from ongoing core business activities in the financials, with related assets and liabilities classified as held for sale as of 30 June 2025.\n \nFinancial Headlines - Continuing Operations\n \n· Group revenue increased 43.1% to £15.4 million (2024: £10.8 million) and growth of 12.4% on a proforma1 basis.\n· Gross profit increased 49.9% to £6.6 million (2024: £4.4 million) and gross margin improvement to 43.1% (2024: 41.2%) (2024 proforma: 43.0%).\n· Marketing costs as % of revenue increased to 10.5% (2024: 5.6%).\n· Adjusted EBITDA2 increased 32.6% to £1.8 million (2024: £1.4 million) and adjusted EBITDA margin declined to 11.6% (2024: 12.6%) (2024 proforma: 10.9%).\n· Operating loss increased to £1.4 million (2024: £0.4 million) and Adjusted profit before tax3 increased to £0.8 million (2024: £0.1 million).\n· &nbs...